Altshuler Shaham Ltd Reduces Stock Holdings in Kamada Ltd. (NASDAQ:KMDA)

Altshuler Shaham Ltd lessened its position in shares of Kamada Ltd. (NASDAQ:KMDA) by 49.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 132,935 shares of the biotechnology company’s stock after selling 132,330 shares during the quarter. Altshuler Shaham Ltd owned approximately 0.23% of Kamada worth $816,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. EWA LLC acquired a new position in Kamada during the fourth quarter worth about $68,000. Y.D. More Investments Ltd acquired a new position in shares of Kamada during the 3rd quarter worth approximately $75,000. Finally, Meitav Investment House Ltd. lifted its stake in Kamada by 17.2% in the 3rd quarter. Meitav Investment House Ltd. now owns 76,835 shares of the biotechnology company’s stock valued at $412,000 after buying an additional 11,284 shares in the last quarter. 20.38% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Kamada in a research report on Thursday.

Kamada Trading Down 3.1 %

Shares of Kamada stock traded down $0.18 during mid-day trading on Thursday, hitting $5.56. 26,749 shares of the stock were exchanged, compared to its average volume of 22,688. The company has a 50-day simple moving average of $5.57 and a 200 day simple moving average of $5.51. The stock has a market capitalization of $319.59 million, a price-to-earnings ratio of 38.27 and a beta of 1.05. Kamada Ltd. has a twelve month low of $4.08 and a twelve month high of $6.53.

Kamada (NASDAQ:KMDA) last announced its earnings results on Wednesday, March 6th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.04. The firm had revenue of $36.43 million for the quarter, compared to analyst estimates of $37.71 million. Kamada had a net margin of 5.81% and a return on equity of 5.66%. Equities research analysts forecast that Kamada Ltd. will post 0.23 earnings per share for the current fiscal year.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.